The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and
pathologic diagnosis of DLB incorporating new information about the core clinical features …

Dementia has been increasingly more recognized to be a common feature in patients with
Parkinson's disease (PD), especially in old age. Specific criteria for the clinical diagnosis of …

Objective: The authors examined research on effects, costs, and patient and caregiver views
of pharmacological management strategies for Lewy body dementia. Method: Studies were …

Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative
dementia in older people. It is part of the range of clinical presentations that share a neuritic …

Neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and
Huntington's disease currently affect tens of millions of people worldwide. Unfortunately, as …

Lewy bodies were first discovered in neurons by the German neurologist Dr Friedrich Lewy
in 1912 while he was studying the neuropathology of Parkinson disease (PD) in the …

Cognitive impairment is common in Parkinson's disease (PD) and involves attentional,
executive, visuospatial, and memory dysfunctions. Dementia is more frequently encountered …

Parkinson's disease (PD) is a common, disabling, neurodegenerative disorder. In addition to
classical motor symptoms, non-motor features are now widely accepted as part of the clinical …

The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to
review and revise its first (2006) Guidelines for clinical practice with anti-dementia drugs. As …

Background: One of the core clinical features of dementia with Lewy bodies (DLB) is
extrapyramidal syndrome (EPS). Levodopa is currently the gold standard oral therapy for …